Publications by authors named "Christophe Dussert"

Object: The first aim of this study was to diagnose more aggressive and potentially recurrent meningiomas using an in vitro embryonic chick heart invasiveness assay in which lysosomal enzyme cathepsin B was used as the invasiveness marker. The second aim was to confirm if cathepsin B and/or cathepsin L and their endogenous inhibitors were also prognostic parameters in the clinical study of 119 patients with meningioma.

Methods: Primary meningioma cultured spheroids were "confronted" with embryonic chick heart spheroids in vitro, and cathepsin B was used as molecular marker to immunolabel the invasive tumor cells.

View Article and Find Full Text PDF

Adrenomedullin (AM) is a multifunctional peptide vasodilator that transduces its effects through calcitonin receptor-like receptor/receptor activity modifying protein-2 and -3 (CLR/RAMP2 and CLR/RAMP3). Previously, we reported on the development of an anti-AM antibody that potently inhibits tumor cell proliferation in vitro and tumor growth in vivo. Here, we report the effect of anti-AM receptor antibodies (alphaAMRs) on angiogenesis and tumor growth.

View Article and Find Full Text PDF

Recently, we demonstrated that U87 glioblastoma xenograft tumors treated with anti-adrenomedullin (AM) antibody were less vascularized than control tumors, suggesting that AM might be involved in neovascularization and/or vessel stabilization. Angiogenesis, the sprouting of new capillaries from preexisting blood vessels, is a multistep process that involves migration and proliferation of endothelial cells, remodeling of the extracellular matrix and functional maturation of the newly assembled vessels. In our study, we analyzed the role of AM on human umbilical vein endothelial cell (HUVEC) phenotype related to different stages of angiogenesis.

View Article and Find Full Text PDF
Article Synopsis
  • Glioblastoma is a highly aggressive brain tumor with no effective treatments, and growth factors like alpha-amidated peptides, particularly adrenomedullin (AM), are potential therapeutic targets due to their role in tumor growth.
  • Researchers found that AM mRNA levels are significantly higher in glioblastoma cells compared to other tumor types, indicating its involvement in tumor progression and growth stimulation.
  • They demonstrated that blocking AM with a specific antibody can reduce glioblastoma cell growth by about 33%, suggesting that targeting AM may be a viable strategy for treating glioblastoma.
View Article and Find Full Text PDF